Edgewise Therapeutics, Inc.
EWTX
Rank in Stocks
#3855
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Share Price
$40.33
Market Cap
$4.34B
Change (1 day)
1.46%
Change (1 year)
160.03%
Country
US
Trade Edgewise Therapeutics, Inc. (EWTX)
Category
Healthcare
Stock price history for Edgewise Therapeutics, Inc. (EWTX)
Highest end of day price: $39.01 on 2026-10-01
Lowest end of day price: $32.43 on 2021-03-01
Lowest end of day price: $32.43 on 2021-03-01
Stock price history of Edgewise Therapeutics, Inc. from 2021 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 37.72% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $518.20 | 21.57% |
US
|
|
| $243.77 | 786.76% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $879.20 | 5.32% |
NL
|
|
| $752.87 | 7.40% |
CH
|
